HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.

Abstract
Nasal-type, extranodal NK/T cell lymphoma (ENKTCL) is a special type of lymphomas with geographic and racial specificity. Up to now, the standard first-line treatment is still not unified. In our previous report, the "sandwich" protocol produced good results. Continuing to use the "sandwich" mode, a new chemotherapy composed of L-asparaginase, cisplatin, etoposide and dexamethasone (LVDP) plus concurrent chemoradiotherapy (CCRT) was conducted in more patients with newly diagnosed, I/II stage ENKTCL. The results showed that 66 patients were enrolled. Overall response rate was 86.4% including 83.3% complete response and 3.0% partial remission. With the median follow-up of 23.5 months, 3-year overall survival and 3-year progression-free survival were 70.1% and 67.4%, respectively. The survival rate in stage II and extra-cavity stage I was significantly less than that in limited stage I (p < 0.05). Therefore, we thought that the "sandwich" mode was worthy of being generalized and LVDP combined with CCRT was an effective protocol for I/II stage ENKTCL. But this regimen was not suitable for all stage I/II patients and warrants larger sample and layering investigation. This study was a registered clinical trial with number ChiCTR-TNC-12002353.
AuthorsMing Jiang, Li Zhang, Li Xie, Hong Zhang, Yu Jiang, Wei-Ping Liu, Wen-Yan Zhang, Rong Tian, Yao-Tiao Deng, Sha Zhao, Li-Qun Zou
JournalOncotarget (Oncotarget) Vol. 8 Issue 30 Pg. 50155-50163 (Jul 25 2017) ISSN: 1949-2553 [Electronic] United States
PMID28404973 (Publication Type: Clinical Trial, Phase II, Journal Article)
Chemical References
  • Etoposide
  • Dexamethasone
  • Asparaginase
  • Cisplatin
Topics
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
  • Asparaginase (pharmacology, therapeutic use)
  • Chemoradiotherapy (methods)
  • Cisplatin (pharmacology, therapeutic use)
  • Dexamethasone (pharmacology, therapeutic use)
  • Etoposide (pharmacology, therapeutic use)
  • Female
  • Humans
  • Lymphoma, Extranodal NK-T-Cell (drug therapy, mortality, pathology, radiotherapy)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prospective Studies
  • Survival Analysis
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: